| Keyword | CPC | PCC | Volume | Score | Length of keyword |
|---|---|---|---|---|---|
| teplizumab diabetes | 1.31 | 0.4 | 3805 | 87 | 19 |
| teplizumab | 1.37 | 0.7 | 3140 | 28 | 10 |
| diabetes | 1.46 | 0.6 | 7710 | 24 | 8 |
| Keyword | CPC | PCC | Volume | Score |
|---|---|---|---|---|
| teplizumab diabetes | 1.71 | 1 | 5820 | 19 |
| teplizumab type 1 diabetes | 1.56 | 0.4 | 788 | 33 |
| teplizumab type 1 diabetes prevention | 0.86 | 0.8 | 731 | 88 |
| american diabetes association teplizumab | 0.85 | 0.6 | 6993 | 4 |
| diabetes uk teplizumab | 1.7 | 0.5 | 7269 | 15 |
| siplizumab type 1 diabetes phase 1 data | 0.87 | 0.9 | 3000 | 34 |
| teplizumab mechanism of action | 0.9 | 0.6 | 2197 | 56 |
| teplizumab mode of action | 0.56 | 0.6 | 8659 | 39 |
| teplizumab fda approval 2022 | 1.42 | 0.2 | 2937 | 43 |
| teplizumab route of administration | 1.38 | 0.7 | 3610 | 80 |
| atezolizumab pd-l1 | 0.5 | 0.1 | 5747 | 23 |
